2138299-29-1 Usage
Uses
Used in Pharmaceutical Industry:
(E)-1-(4-(5-carbamoyl-2-(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1H-benzo[d]imidazol-1-yl)but-2-en-1-yl)-2-(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-7-(3-hydroxypropoxy)-1H-benzo[d]imidazole-5-carboxamide is used as a potential therapeutic agent for various medical conditions due to its complex structure and the presence of bioactive motifs.
Used in Chemical Research:
In the field of chemical research, this molecule can be used as a starting material or a model compound for studying the effects of its various functional groups on its biological activity, reactivity, and potential applications in material science.
Used in Drug Design:
The molecule's complex structure and potential biological activity make it a candidate for drug design, where it could be further modified and optimized to target specific biological pathways or receptors.
Used in Material Science:
Due to its structural complexity and the presence of multiple functional groups, this molecule may have applications in the development of new materials with unique properties, such as advanced polymers or coatings with specific interactions or responses to environmental conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 2138299-29-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 2,1,3,8,2,9 and 9 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 2138299-29:
(9*2)+(8*1)+(7*3)+(6*8)+(5*2)+(4*9)+(3*9)+(2*2)+(1*9)=181
181 % 10 = 1
So 2138299-29-1 is a valid CAS Registry Number.
2138299-29-1Relevant academic research and scientific papers
MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) USEFUL IN TREATING HIV
-
, (2019/04/27)
Disclosed are compounds having the formula: (I-N) wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof, along with combinations thereof, all of which are useful in HIV therapies.
METHODS FOR ADMINISTERING STING AGONISTS
-
, (2019/04/27)
The present invention relates to methods of treating disease states, including cancer, in a human comprising systemically administering a STING agonist, or a pharmaceutically acceptable salt thereof, to said human.
HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS
-
, (2017/11/06)
Disclosed are compounds having the formula (I-N), wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.
